US3414574A - Certain pyrimido (4, 5-b) indoles and intermediates employed in their preparation - Google Patents

Certain pyrimido (4, 5-b) indoles and intermediates employed in their preparation Download PDF

Info

Publication number
US3414574A
US3414574A US632552A US63255267A US3414574A US 3414574 A US3414574 A US 3414574A US 632552 A US632552 A US 632552A US 63255267 A US63255267 A US 63255267A US 3414574 A US3414574 A US 3414574A
Authority
US
United States
Prior art keywords
compound
preparation
indoles
parts
pyrimido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US632552A
Inventor
Albert J Frey
Goetz E Hardtmann
Ott Hans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Sandoz Inc
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Priority to US632552A priority Critical patent/US3414574A/en
Application granted granted Critical
Publication of US3414574A publication Critical patent/US3414574A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • This invention relates to pyrimido[4,5-b]indoles, and more particularly to 3-amido-3,4-dihydro-4-oxo-pyrimido [4,5-b]indoles and salts thereof and a process for the preparation thereof.
  • the invention also relates to intermediates in the preparation of said compounds and a process for preparation of said intermediates.
  • the 3- amido-3,4-dihydro-4-oxo-pyrimido[4,5-b1indoles of this invention may be represented structurally as follows:
  • R is a member selected from the group consisting of a hydrogen atom, chloro and methoxy
  • R is a member selected from the group consisting of a hydrogen atom, and linear alkyl having from I to 3 atoms, i.e., methyl, ethyl and propyl.
  • Step a involves the 3,414,574 Patented Dec. 3, 1968 ice preparation of a Compound III, i.e., a hydrazide, from a Compound II, i.e., a Z-aminoindol-3-carboxylic acid lower linear alkyl ester, in a conventional manner. It is preferred to prepare the Compound III by heating a Compound II in a large excess of anhydrous hydrazine, e.g., 5 to 20 fold by weight, under reflux. If desired the reaction may be carried out in a suitable solvent, e.g., toluene, using from 1 to 2 molar equivalents of hydrazine and at to 120.
  • a suitable solvent e.g., toluene
  • Step b is a cyclization of the Compound III to the corresponding Compound I, which is effected by heating at from to boiling, preferably by refluxing, a Compound III in a large excess, e.g., 5 to 40 fold by weight, of a Compound IV, which is a lower linear fatty acid having from 1 to4 carbon atoms, i.e., formic acid, acetic acid, propionic acid or butyric acid.
  • the cyclization can be carried out in a suitable solvent, e.g., xylene, using from 2 to 4 equivalents of the Compound IV at temperatures of from 90 to the boiling point of the Compound IV.
  • Compounds II may be obtained according to the procedure described by C. A. Grob and O. Weissbach in Helvetica Chimica Acta, volume 44, pages 1748 to 1753 (1961).
  • Compounds I are useful because they have pharmacological activity. They are useful as antihypertensives and diuretics. They are administered to mammals either orally or parenterally in daily doses of from 5 to 20 mg./kg. of body weight, e.g., for large mammals from 300' to 1200 milligrams per diern, preferably administered in doses of from 75 to 600 milligrams; a single daily oral dose is also acceptable.
  • the compounds may be combined with a pharmaceutically acceptable carrier, and such other conventional adjuvants, as may be necessary, and administered orally in such forms as tablets, capsules, elixirs, suspensions or solutions, or parenterally in such forms as injectable solutions, suspensions or emulsions.
  • a pharmaceutically acceptable carrier such other conventional adjuvants, as may be necessary, and administered orally in such forms as tablets, capsules, elixirs, suspensions or solutions, or parenterally in such forms as injectable solutions, suspensions or emulsions.
  • the compounds may be similarly administered in the form of their non-toxic pharmaceutically ac ceptable acid addition salts.
  • Such salts possess the same order of activity as the free base are readily prepared in conventional manner by reacting the base with the appropriate acid and accordingly are included within the scope of the invention.
  • Such salts are the mineral acid salts such as the hydrochloride, hydrobromide, sulfate, phosphate and the like and the organic acid salts such as the succinate, benzoate, acetate, maleate, p-toluenesulfonate, benzenesulfonate and the like.
  • each of the pharmaceutically active compounds of this invention may be incorporated, for oral administration, in a tablet as the sole active ingredient.
  • a typical tablet is constituted by from 1 to 3 percent binder, e.g., tragacanth; from 3 to 10 percent disintegrating agent, e.g., corn starch; from 2 to 10 percent lubricant, e.g., talcum; from 0.25 to 1.0 percent lubricant, e.g., magnesium stearate; and average dosage of active ingredient; and q.s. percent of filler, e.g., lactose; all percentages being by weight.
  • Tablets are prepared according to standard tabletting techniques, which are wellknown in the art, employing the necessary amounts of conventional granulating liquids, e.g., alcohol SD-30 and purified water.
  • An exemplary tabletting formulation for the instant active compounds is:
  • Alcohol SD-30 purified water, q.s.
  • the title compound of the example is also useful as an appetite suppressant.
  • R is a member selected from the group consisting of a hydrogen atom, chloro and methoxy. 4. The compound according to claim 3 wherein R is a hydrogen atom.
  • NICHOLAS S. RIZZO Primary Examiner.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Description

United States Patent 3,414,574 CERTAIN PYRIMIDO(4,5-b)INDOLES AND INTERMEDIATES EMPLOYED IN THEIR PREPARATION Albert J. Frey, Essex Fells, Goetz E. Hardtrnann, Florham Park, and Hans Ott, Convent Station, N.J., assignors to Sandoz Inc., Hanover, NJ.
No Drawing. Filed Apr. 21, 1967, Ser. No. 632,552 4 Claims. (Cl. 260256.4)
ABSTRACT OF THE DISCLOSURE This invention relates to pyrimido[4,5-b]indoles, and more particularly to 3-amido-3,4-dihydro-4-oxo-pyrimido [4,5-b]indoles and salts thereof and a process for the preparation thereof. The invention also relates to intermediates in the preparation of said compounds and a process for preparation of said intermediates. The 3- amido-3,4-dihydro-4-oxo-pyrimido[4,5-b1indoles of this invention may be represented structurally as follows:
0 5 H H 0 REE J 2 R N N/ 2 I 8 l wherein R is a member selected from the group consisting of a hydrogen atom, chloro and methoxy; and
R is a member selected from the group consisting of a hydrogen atom, and linear alkyl having from I to 3 atoms, i.e., methyl, ethyl and propyl.
Compounds I are obtained according to the procedure of the folliwing reaction scheme wherein R and R are as defined above and R is lower linear alkyl, e.g., having from 1 to 6 carbon atoms:
According to the reaction scheme, Step a involves the 3,414,574 Patented Dec. 3, 1968 ice preparation of a Compound III, i.e., a hydrazide, from a Compound II, i.e., a Z-aminoindol-3-carboxylic acid lower linear alkyl ester, in a conventional manner. It is preferred to prepare the Compound III by heating a Compound II in a large excess of anhydrous hydrazine, e.g., 5 to 20 fold by weight, under reflux. If desired the reaction may be carried out in a suitable solvent, e.g., toluene, using from 1 to 2 molar equivalents of hydrazine and at to 120.
Step b is a cyclization of the Compound III to the corresponding Compound I, which is effected by heating at from to boiling, preferably by refluxing, a Compound III in a large excess, e.g., 5 to 40 fold by weight, of a Compound IV, which is a lower linear fatty acid having from 1 to4 carbon atoms, i.e., formic acid, acetic acid, propionic acid or butyric acid. If desired, the cyclization can be carried out in a suitable solvent, e.g., xylene, using from 2 to 4 equivalents of the Compound IV at temperatures of from 90 to the boiling point of the Compound IV.
Compounds II may be obtained according to the procedure described by C. A. Grob and O. Weissbach in Helvetica Chimica Acta, volume 44, pages 1748 to 1753 (1961).
Compounds I are useful because they have pharmacological activity. They are useful as antihypertensives and diuretics. They are administered to mammals either orally or parenterally in daily doses of from 5 to 20 mg./kg. of body weight, e.g., for large mammals from 300' to 1200 milligrams per diern, preferably administered in doses of from 75 to 600 milligrams; a single daily oral dose is also acceptable.
For the above uses, the compounds may be combined with a pharmaceutically acceptable carrier, and such other conventional adjuvants, as may be necessary, and administered orally in such forms as tablets, capsules, elixirs, suspensions or solutions, or parenterally in such forms as injectable solutions, suspensions or emulsions. Furthermore, the compounds may be similarly administered in the form of their non-toxic pharmaceutically ac ceptable acid addition salts. Such salts possess the same order of activity as the free base, are readily prepared in conventional manner by reacting the base with the appropriate acid and accordingly are included within the scope of the invention. Representative of such salts are the mineral acid salts such as the hydrochloride, hydrobromide, sulfate, phosphate and the like and the organic acid salts such as the succinate, benzoate, acetate, maleate, p-toluenesulfonate, benzenesulfonate and the like.
For example, each of the pharmaceutically active compounds of this invention may be incorporated, for oral administration, in a tablet as the sole active ingredient. A typical tablet is constituted by from 1 to 3 percent binder, e.g., tragacanth; from 3 to 10 percent disintegrating agent, e.g., corn starch; from 2 to 10 percent lubricant, e.g., talcum; from 0.25 to 1.0 percent lubricant, e.g., magnesium stearate; and average dosage of active ingredient; and q.s. percent of filler, e.g., lactose; all percentages being by weight. Tablets are prepared according to standard tabletting techniques, which are wellknown in the art, employing the necessary amounts of conventional granulating liquids, e.g., alcohol SD-30 and purified water. An exemplary tabletting formulation for the instant active compounds is:
Parts Title compound of the example 75 Tragacanth 2 Lactose 14.5 Corn starch 5 Talcum 3 Magnesium stearate 0.5
Alcohol SD-30, purified water, q.s.
The title compound of the example is also useful as an appetite suppressant.
An example illustrative of this invention follows. Throughout this disclosure all temperatures are centigrade (room temperature is 20) and all percents and parts are by weight, unless specified otherwise. Parts by weight are related to parts by volume as a kilogram is related to a liter.
EXAMPLE 3-formamido-3,4-dihydro-4-oxo-pyrimido [-4,5-b]indole This example illustrates the preparation of a Compound I according to the reaction scheme presented above.
(a) 2-aminoindol-3-carboxylic acid hydrazide Dissolve parts of 2-aminoindo1e-3-carboxy1ic acid ethyl ester in 100 parts by volume of 95% anhydrous hydrazine and reflux the mixture for hours. Cool the mixture and evaporate under vacuum to obtain a resi due. Dissolve the residue in methanol and remove the residual hydrazine by evaporating under vacuum. Crystallize the residue from ethanol to obtain crude Compound a, then recrystallize from ethanol-chloroform (2:1) to obtain purified Compound a, melting point (M.P.) 201 to 205.
(b) 3-form amide-3,4-dihydro-4-ox0-pyrimido- [4,5 -b] indole Reflux a mixture of 10.4 parts of purified Compound a and 200 parts by volume of 98 to 100% formic acid for 15 hours. Dilute the reaction mixture with 400 parts by volume of water, to form a precipitate of crude title compound, which then separate by filtration and wash on the filter first with 200 parts by volume of water then 50 parts by volume of ethanol and finally 100 parts by volume of diethyl ether. Recrystallize from 500 parts by volume of ethanol-dioxane (1:1) to obtain the purified title compound, M.P. 312 to 315.
Following the procedure described in Step a of this example but replacing the 2-aminoindole-3-carboxylic acid ethyl ester with an equivalent amount of 4-chloro-2- l H I U A J wherein R is a member selected from the group consisting of a hydrogen atom, chloro and methoxy; and R is a member selected from the group consisting of a hydrogen atom, methyl, ethyl and propyl; and (B) a pharmaceutically acceptable acid addition salt of a compound of said formula.
2. The compound according to claim 1 wherein each of R and R is a hydrogen atom.
3. A compound of the formula:
wherein R is a member selected from the group consisting of a hydrogen atom, chloro and methoxy. 4. The compound according to claim 3 wherein R is a hydrogen atom.
References Cited UNITED STATES PATENTS 3,320,278 5/1967 Ruyle et a1. 260-32614 FOREIGN PATENTS 1,363,855 5/1964 France.
OTHER REFERENCES Magidson et al., Chem. Abstracts, vol. 64 (1966), col. 19634.
NICHOLAS S. RIZZO, Primary Examiner.
R. J. GALLAGHER, Assistant Examiner.
US632552A 1967-04-21 1967-04-21 Certain pyrimido (4, 5-b) indoles and intermediates employed in their preparation Expired - Lifetime US3414574A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US632552A US3414574A (en) 1967-04-21 1967-04-21 Certain pyrimido (4, 5-b) indoles and intermediates employed in their preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US632552A US3414574A (en) 1967-04-21 1967-04-21 Certain pyrimido (4, 5-b) indoles and intermediates employed in their preparation

Publications (1)

Publication Number Publication Date
US3414574A true US3414574A (en) 1968-12-03

Family

ID=24535965

Family Applications (1)

Application Number Title Priority Date Filing Date
US632552A Expired - Lifetime US3414574A (en) 1967-04-21 1967-04-21 Certain pyrimido (4, 5-b) indoles and intermediates employed in their preparation

Country Status (1)

Country Link
US (1) US3414574A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011324A (en) * 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
US4044134A (en) * 1974-07-05 1977-08-23 Pfizer Inc. Fused pyrimidin-4(3H)-ones as antiallergy agents
US4072679A (en) * 1976-06-15 1978-02-07 E. R. Squibb & Sons, Inc. 1,4- AND 4,10-DIHYDRO-4-OXO-PYRIMIDO (1,2-A)-benzimidazole-3-carboxylic acids, esters and amides
CN104804002A (en) * 2015-04-08 2015-07-29 河南师范大学 Synthesis method for 9H-pyrimido(4,5-b) indole compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1363855A (en) * 1960-02-04 1964-06-19 Roussel Uclaf New indole derivatives and their preparation process
US3320278A (en) * 1965-06-30 1967-05-16 Merck & Co Inc Alpha-(2-amino)-3-indolyl lower aliphatic acid derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1363855A (en) * 1960-02-04 1964-06-19 Roussel Uclaf New indole derivatives and their preparation process
US3320278A (en) * 1965-06-30 1967-05-16 Merck & Co Inc Alpha-(2-amino)-3-indolyl lower aliphatic acid derivatives

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044134A (en) * 1974-07-05 1977-08-23 Pfizer Inc. Fused pyrimidin-4(3H)-ones as antiallergy agents
US4011324A (en) * 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
US4072679A (en) * 1976-06-15 1978-02-07 E. R. Squibb & Sons, Inc. 1,4- AND 4,10-DIHYDRO-4-OXO-PYRIMIDO (1,2-A)-benzimidazole-3-carboxylic acids, esters and amides
US4109091A (en) * 1976-06-15 1978-08-22 E. R. Squibb & Sons, Inc. Derivatives of 1,4- and 4,10-dihydro-4-oxo-pyrimido[1,2-a]benzimidazole-3-carboxylic acid amides
CN104804002A (en) * 2015-04-08 2015-07-29 河南师范大学 Synthesis method for 9H-pyrimido(4,5-b) indole compounds

Similar Documents

Publication Publication Date Title
US4148897A (en) 1,2-Dihydronaphthalene derivatives and pharmaceutical composition
US3419569A (en) Indole derivatives
US4690924A (en) 1,7-Naphthyridine derivatives and medicinal preparations containing same
AU692563B2 (en) Novel pyrrolocarbazoles
US3335134A (en) Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
US3542782A (en) 5,6-dihydro-8h-isoquino(1,2-b)quinazolines
US3414574A (en) Certain pyrimido (4, 5-b) indoles and intermediates employed in their preparation
EP0028381B1 (en) Azepinoindoles, process for their production and pharmaceutical compositions containing them
US3652569A (en) Ergonine ergoptine and the 1-methyl and 9 10-dihydro derivatives thereof
US4622320A (en) Oxadiazolylimidazobenzodiazepine, compositions, and method
IE46908B1 (en) Pyridobenzodiazepines
US3666762A (en) 2{40 {62 -ISOPROPYL-5{40 {60 -n-PROPYL-9,10-DIHYDRO-ERGOPEPTINES
CS199610B2 (en) Process for preparing 8-8-disubstituted 6-methylergolines and derivatives thereof
JPS6245864B2 (en)
US3818096A (en) Compositions of 1,2-dilower alkyl arylpyrazolium quaternary salts and method of lowering blood sugar levels with same
US3579517A (en) Secondaryamino pyridazines
US3496165A (en) Octahydro-3-benzazecines
US4377689A (en) Process for preparing spiro derivatives
US3655648A (en) 2 5-benzodiazonin-3-ones
US3459750A (en) Asymmetrical triazines
US3647877A (en) Aminopropionanilides
US3497499A (en) Dibenzo(b,h)(1,5)diazecines
US3530129A (en) 8h-isoquino(1,2-b)quinazolin-8-ones
US3551411A (en) 2,5-benzodiazonine compounds
US4745112A (en) Oxadiazolylimidazobenzodiazepine, compositions, and method III